Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $516 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,230 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Cetrelimab (JNJ 63723283) is a humanized anti-PD-1 monoclonal antibody that dose-dependently increases T cell-mediated cytokine production and stimulates cytokine expression. It is used in multiple myeloma and bladder cancer research. |
Targets&IC50 | PD-L1:111.7 ng/mL, PD-L2:138.6 ng/mL |
In vitro | Cetrelimab targets a human IgG4 κmonoclonal antibody to PD-1. Cetrelimab blocks the interaction of PD-1 with PD-L1 and PD-L2 (IC50 of 111.7 ng/mL and 138.6 ng/mL, respectively). The EC50 value of cetrelimab was 0.4138 μg/mL (HEK-293 cells), and the Kd of binding PD-1 was 1.72 nM (HEK293 cells). [1] |
In vivo | Cetrelimab (10 mg/kg, 21 days) reduced mean MC38 tumor volume in PD-1 knockin mice (hPD-1KI). In a PDX lung mouse model, cetrelimab (10 mg/kg every 5 days for 6 cycles) increased the number of peripheral T cells and reduced the average tumor volume. [1] |
Alias | JNJ63723283, JNJ3283, JNJ 63723283, JNJ 3283 |
Cas No. | 2050478-92-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.